OncoCyte Corp expected to post a loss of 24 cents a share - Earnings Preview

Insight Molecular Diagnostics

10/05/2025 01:38

OncoCyte Corp OCX.OQ OCX.O is expected to show a fall in quarterly revenue when it reports  results on May 12 for the period ending March 31 2025

The Irvine California-based  company is expected to report a 28.0% decrease in revenue to $126.75 thousand from $176 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for OncoCyte Corp is for a loss of 24 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for OncoCyte Corp is $4.50‚Äč, above‚Äč its last closing price of $2.87. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.44
-0.43
-1.93
Missed
-351.6
Sep. 30 2024
-0.44
-0.44
-0.98
Missed
-124.8
Jun. 30 2024
-0.55
-0.56
-0.36
Beat
35.6‚Äč
Mar. 31 2024
-0.65
-0.67
-1.13
Missed
-69.1
‚Äč‚ÄčDec. 31 2023
-1.14
-2.12
Missed
-86.5
Sep. 30 2023
-1.00
-1.01
-0.81
Beat
19.6‚Äč
Jun. 30 2023
-0.68
-1.30
-1.07
Beat
17.7
Mar. 31 2023
-1.31
-1.84
0.40
Beat
121.7

This summary was machine generated May 10 at 00:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)